



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	68.42
Trade Time:	4:00 PM ET Sep 20, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	26.54 - 70.23
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Sep 7, 2018*  
[German Health Technology Assessment Body \(IQWiG\) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results](#)
- Aug 2, 2018*  
[Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress](#)
- Jul 26, 2018*  
[Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018](#)
- Jun 3, 2018*  
[Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving](#)

*May 30, 2018*  
[Genomic Health to Present at Jefferies 2018 Global Healthcare Conference](#)

## Financials & Filings [\[ View all \]](#)

- Mar 14, 2018*  
[Annual Report \(10-K\)](#)
- Apr 27, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 7, 2018*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2018*  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)

